v3.26.3
Segment Information (Tables)
 9 Months Ended
Sep. 25, 2026
Segment Reporting [Abstract]  
Segment Results Detailed segment data for the three and nine-month periods ended September 25, 2026 and September 26, 2025 is as follows ($ in millions):
BiotechnologyLife SciencesDiagnosticsTotal Reportable Segments
Other (a)
Total
For the Three-Month Period Ended September 25, 2026:
Sales$1,807 $1,865 $2,882 $6,554 $— $6,554 
Less:
Depreciation(44)(48)(113)(205)(3)(208)
Amortization of intangible assets(227)(153)(133)(513)— (513)
Impairments (b)
(52)— — (52)— (52)
Acquisition-related items (c)
— — (84)(84)— (84)
Other segment items (d)
(1,007)(1,405)(1,938)(4,350)(102)(4,452)
Operating profit$477 $259 $614 $1,350 $(105)$1,245 
For the Three-Month Period Ended September 26, 2025:
Sales$1,798 $1,792 $2,463 $6,053 $— $6,053 
Less:
Depreciation(38)(47)(101)(186)(3)(189)
Amortization of intangible assets(231)(154)(48)(433)— (433)
Impairments (b)
(86)— (15)(101)— (101)
Other segment items (d)
(1,091)(1,369)(1,634)(4,094)(82)(4,176)
Operating profit$352 $222 $665 $1,239 $(85)$1,154 
BiotechnologyLife SciencesDiagnosticsTotal Reportable Segments
Other (a)
Total
For the Nine-Month Period Ended September 25, 2026:
Sales$5,524 $5,481 $7,765 $18,770 $— $18,770 
Less:
Depreciation(124)(144)(322)(590)(7)(597)
Amortization of intangible assets(692)(456)(262)(1,410)— (1,410)
Impairments (b)
(52)— — (52)— (52)
Acquisition-related items (c)
— — (209)(209)— (209)
Other segment items (d)
(3,089)(4,153)(5,268)(12,510)(276)(12,786)
Operating profit$1,567 $728 $1,704 $3,999 $(283)$3,716 
For the Nine-Month Period Ended September 26, 2025:
Sales$5,260 $5,249 $7,221 $17,730 $— $17,730 
Less:
Depreciation(110)(137)(301)(548)(7)(555)
Amortization of intangible assets(672)(453)(144)(1,269)— (1,269)
Impairments (b)
(101)(432)(15)(548)— (548)
Other segment items (d)
(3,053)(4,043)(4,824)(11,920)(250)(12,170)
Operating profit$1,324 $184 $1,937 $3,445 $(257)$3,188 
(a) Other consists of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance.
(b) For information on the impairments, refer to Note 9.
(c) For information on acquisition activity, refer to Note 2.
(d) Other segment items for each reportable segment include cost of sales, selling, general and administrative (“SG&A”) expenses and research and development (“R&D”) expenses, excluding in each case depreciation, amortization of intangible assets, impairments and acquisition-related items. Included within these categories of expenses are overhead expenses, stock compensation expense, restructuring charges and allocated corporate expenses.
The following table presents identifiable assets as of September 25, 2026 and December 31, 2025 ($ in millions):
September 25, 2026December 31, 2025
Biotechnology$35,504 $37,337 
Life Sciences22,645 23,112 
Diagnostics25,785 14,748 
Other9,347 8,267 
Total$93,281 $83,464 
The following table presents capital expenditures, gross for the three and nine-month periods ended September 25, 2026 and September 26, 2025 ($ in millions):
Three-Month Period EndedNine-Month Period Ended
September 25, 2026September 26, 2025September 25, 2026September 26, 2025
Biotechnology$56 $94 $186 $255 
Life Sciences44 40 109 129 
Diagnostics155 157 463 397 
Other— 1 3 4 
Total$255 $292 $761 $785